
  
    
      
        Background_NNP
        Prostate_NNP cancer_NN (_( PCA_NNP )_) is_VBZ the_DT leading_VBG cause_NN of_IN death_NN in_IN
        the_DT American_JJ male_JJ over_IN age_NN 55_CD ,_, according_VBG to_TO recent_JJ data_NNS [_NN 1_CD
        ]_NN ._. To_TO date_NN ,_, the_DT mechanisms_NNS underlying_VBG the_DT pathogenesis_NNS of_IN
        this_DT disease_NN ,_, including_VBG how_WRB normal_JJ prostate_NN cells_NNS become_VBP
        neoplastic_JJ ,_, remain_VB unidentified_JJ ._. Moreover_RB ,_, the_DT treatment_NN
        efficacy_NN of_IN this_DT disease_NN remains_VBZ limited_VBN ,_, especially_RB when_WRB
        it_PRP recurs_NNS ._. A_DT thorough_JJ understanding_NN of_IN the_DT neoplastic_JJ
        process_NN could_MD facilitate_VB earlier_JJR detection_NN of_IN the_DT disease_NN ,_,
        lead_VB to_TO more_RBR specific_JJ therapies_NNS for_IN PCA_NNP ,_, and_CC ultimately_RB
        improve_VB survival_NN ._.
        PCA_NNP is_VBZ one_CD of_IN several_JJ types_NNS of_IN cancers_NNS in_IN which_WDT IL-_NNP 6_CD has_VBZ
        been_VBN found_VBN or_CC is_VBZ thought_VBN to_TO play_VB a_DT pathophysiological_JJ role_NN ._.
        Some_DT researchers_NNS think_VBP IL-_NNP 6_CD may_MD play_VB a_DT role_NN in_IN PCA_NNP because_IN
        of_IN what_WP IL-_NNP 6_CD does_VBZ in_IN other_JJ model_NN systems_NNS of_IN cancer_NN biology_NN ._.
        For_IN example_NN ,_, early_JJ investigators_NNS observed_VBD that_DT transfection_NN
        of_IN untransformed_JJ B_NNP cells_NNS with_IN a_DT plasmid_NN for_IN constitutive_JJ
        expression_NN of_IN IL-_NNP 6_CD conferred_VBD the_DT tumorigenic_JJ phenotype_NN on_IN
        the_DT cells_NNS [_NN 2_CD ]_NN ._. IL-_NNP 6_CD is_VBZ a_DT key_JJ factor_NN in_IN myeloma_NN
        progression_NN and_CC survival_NN [_NN 3_CD 4_CD ]_NN ,_, and_CC also_RB in_IN Kaposi_NNP 's_POS
        sarcoma_NN ,_, a_DT solid_JJ tumor_NN [_NN 5_CD ]_NN ._. In_IN myeloma_NN ,_, the_DT standard_JJ
        therapy_NN for_IN treatment_NN includes_VBZ prednisone_NN ,_, which_WDT acts_VBZ by_IN
        inhibiting_VBG IL-_NNP 6_CD synthesis_NN ._. Experimental_NNP anti-_NN IL-_NNP 6_CD therapies_NNS
        for_IN myeloma_NN and_CC B-_NNP lymphoproliferative_JJ disorders_NNS have_VBP been_VBN
        shown_VBN to_TO be_VB of_IN some_DT use_NN in_IN limited_JJ clinical_JJ trials_NNS [_NN 6_CD 7_CD 8_CD
        9_CD 10_CD 11_CD ]_NN ,_, therefore_RB this_DT is_VBZ an_DT intensely-studied_JJ target_NN
        for_IN myeloma_NN therapy_NN ._.
        As_IN mentioned_VBN above_IN ,_, IL-_NNP 6_CD is_VBZ a_DT cytokine_NN that_IN functions_NNS as_IN
        a_DT necessary_JJ growth_NN factor_NN in_IN several_JJ cancer_NN types_NNS ,_, most_RBS
        studied_VBN in_IN multiple_JJ myeloma_NN [_NN 12_CD ]_NN ._. It_PRP is_VBZ an_DT essential_JJ
        factor_NN in_IN the_DT development_NN and_CC maintenance_NN of_IN B_NNP cell_NN
        neoplasms_NNS [_NN 13_CD ]_NN ,_, and_CC likely_JJ plays_VBZ an_DT important_JJ role_NN in_IN
        many_JJ other_JJ types_NNS of_IN cancer_NN ._. IL-_NNP 6_CD signals_NNS through_IN a_DT set_NN of_IN
        signaling_VBG proteins_NNS of_IN the_DT JAK_NNP and_CC STAT_NNP kinase_NN families_NNS [_NN 14_CD
        ]_NN ._. The_DT JAK_NNP and_CC STAT_NNP kinases_NNS are_VBP activated_VBN by_IN
        phosphorylation_NN initiated_VBN by_IN the_DT homodimerization_NN of_IN the_DT
        IL-_NNP 6_CD /_NN IL-_NNP 6_CD receptor_NN complex_JJ on_IN the_DT cell_NN surface_NN ._. The_DT major_JJ
        IL-_NNP 6_CD signaling_VBG intermediates_NNS are_VBP JAK_NNP 2_CD and_CC STAT_NNP 3_CD [_NN 15_CD ]_NN ._.
        Homodimerization_NNP of_IN the_DT IL-_NNP 6_CD /_NN receptor_NN complex_JJ induces_VBZ the_DT
        autophosphorylation_NN of_IN JAK_NNP 2_CD ._. The_DT now-activated_JJ JAK_NNP 2_CD
        phosphorylates_NNS STAT_NNP 3_CD ,_, which_WDT forms_VBZ homodimers_NNS ,_, can_MD cross_VB the_DT
        nuclear_JJ membrane_NN and_CC function_NN as_IN a_DT transcription_NN factor_NN ,_,
        inducing_VBG various_JJ genes_NNS including_VBG genes_NNS involved_VBN in_IN the_DT
        cellular_JJ transformation_NN process_NN [_NN 15_CD ]_NN ._.
        An_DT association_NN between_IN autocrine_NN IL-_NNP 6_CD and_CC PCA_NNP has_VBZ been_VBN
        known_VBN for_IN some_DT time_NN [_NN 16_CD 17_CD ]_NN ._. The_DT change_NN in_IN prostate_NN cell_NN
        phenotype_NN from_IN paracrine_NN IL-_NNP 6_CD -_: stimulated_VBN to_TO autocrine_NN
        IL-_NNP 6_CD -_: stimulated_VBN is_VBZ believed_VBN to_TO be_VB a_DT contributing_VBG factor_NN in_IN
        the_DT progression_NN from_IN benign_JJ hyperplasia_NN to_TO neoplasia_NN [_NN 17_CD ]_NN
        ._. IL-_NNP 6_CD is_VBZ also_RB implicated_VBN in_IN the_DT development_NN of_IN cancer_NN cell_NN
        resistance_NN to_TO chemotherapy_NN in_IN PCA_NNP patients_NNS [_NN 18_CD 19_CD ]_NN ._. In_IN
        other_JJ studies_NNS ,_, a_DT chimeric_JJ protein_NN consisting_VBG of_IN an_DT
        anti-_NN IL-_NNP 6_CD Ab_NNP fused_JJ to_TO 
        Pseudomonas_NNP exotoxin_NN was_VBD found_VBN to_TO
        inhibit_VB proliferation_NN of_IN prostate_NN carcinoma_NN cell_NN lines_NNS [_NN 20_CD
        ]_NN ._. Exogenous_NNP IL-_NNP 6_CD activated_VBN androgen_NN responsive_JJ gene_NN
        expression_NN in_IN the_DT absence_NN of_IN androgens_NNS in_IN human_JJ LNCaP_NNP cells_NNS
        [_NN 21_CD ]_NN ._. More_JJR work_NN is_VBZ needed_VBN to_TO clarify_VB the_DT role_NN of_IN IL-_NNP 6_CD in_IN
        prostate_NN neoplasia_NN ._.
        While_IN there_EX is_VBZ some_DT evidence_NN suggesting_VBG IL-_NNP 6_CD -_: mediated_JJ
        neoplasia_NN in_IN PCA_NNP development_NN [_NN 17_CD 22_CD ]_NN ,_, a_DT system_NN suitable_JJ
        for_IN following_VBG the_DT transformation_NN of_IN prostate_NN cells_NNS during_IN
        PCA_NNP development_NN remains_VBZ lacking_VBG ._. We_PRP chose_VBD to_TO use_VB the_DT
        NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cell_NN lines_NNS ,_, derived_VBN by_IN Danielpour_NNP ,_, et_CC
        al_NN ._. [_NN 23_CD ]_NN ,_, to_TO examine_VB the_DT question_NN of_IN IL-_NNP 6_CD -_: mediated_JJ
        neoplastic_JJ progression_NN via_IN STAT_NNP 3_CD activation_NN ._. The_DT 2_CD lines_NNS
        were_VBD derived_VBN from_IN the_DT same_JJ part_NN of_IN the_DT rat_NN prostate_NN ,_,
        following_VBG treatment_NN in_IN vivo_NN with_IN 
        N_NNP -_: methyl-_NN 
        N_NNP -_: nitrosourea_NN ._. The_DT NRP-_NNP 152_CD cells_NNS are_VBP
        immortalized_JJ but_CC not_RB transformed_VBN ,_, require_VB several_JJ growth_NN
        factors_NNS for_IN in_IN vitro_NN survival_NN ,_, and_CC do_VBP not_RB give_VB rise_NN to_TO
        tumors_NNS in_IN vivo_NN ._. The_DT NRP-_NNP 154_CD cells_NNS are_VBP transformed_VBN ,_, grow_VB in_IN
        the_DT absence_NN of_IN exogenous_JJ growth_NN factors_NNS ,_, and_CC are_VBP
        tumorigenic_JJ [_NN 23_CD 24_CD 25_CD 26_CD 27_CD ]_NN ._. These_DT lines_NNS come_VBP from_IN
        epithelial_NN cells_NNS ._. While_IN prostatic_JJ epithelium_NN is_VBZ resistant_JJ
        to_TO neoplastic_JJ transformation_NN ,_, it_PRP is_VBZ not_RB resistant_JJ to_TO the_DT
        development_NN of_IN hyperplasia_NN ._. Studying_NNP the_DT neoplastic_JJ
        transformation_NN events_NNS in_IN a_DT cell_NN type_NN inherently_RB resistant_JJ
        to_TO this_DT type_NN of_IN change_NN can_MD yield_VB much_JJ valuable_JJ information_NN
        about_IN the_DT transformation_NN process_NN in_IN prostate_NN cells_NNS ._.
      
      
        Materials_NNS &_CC Methods_NNP
        
          Cell_NNP lines_NNS and_CC growth_NN media_NNS
          The_DT tumorigenic_JJ (_( NRP-_NNP 154_CD )_) and_CC non-tumorigenic_JJ
          (_( NRP-_NNP 152_CD )_) rat_NN prostate_NN epithelial_NN cell_NN lines_NNS were_VBD the_DT
          gift_NN of_IN Dr_NNP ._. David_NNP Danielpour_NNP ,_, Ireland_NNP Cancer_NNP Center_NNP ,_,
          University_NNP Hospital_NNP of_IN Cleveland_NNP ,_, Case_NNP Western_NNP Reserve_NNP
          University_NNP ,_, Cleveland_NNP ,_, OH_NNP [_NN 23_CD ]_NN ._. NRP-_NNP 152_CD cells_NNS were_VBD
          propagated_JJ in_IN DMEM_NNP /_NN Ham_NNP 's_POS F_NN 12_CD medium_NN (_( 1_CD :_: 1_CD ;_: GIBCO_NNP )_)
          supplemented_JJ with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( GIBCO_NNP )_) ,_, 2_CD mM_NN
          glutamine_NN (_( GIBCO_NNP )_) ,_, epidermal_NN growth_NN factor_NN (_( 20_CD ng_NN /_NN ml_NN )_) ,_,
          insulin_NN (_( 5_CD μg_NN /_NN ml_NN )_) ,_, dexamethasone_NN (_( 0_CD ._. 1_LS μM_NN )_) and_CC cholera_NN
          toxin_NN (_( 10_CD μg_NN /_NN ml_NN ;_: all_DT reagents_NNS listed_VBN ,_, Sigma_NNP )_) ,_, pH_NN 7_CD ._. 3_CD ._.
          NRP-_NNP 154_CD cells_NNS were_VBD grown_VBN in_IN DMED_NNP /_NN F_NN 12_CD plus_CC serum_NN and_CC
          dexamethasone_NN only_RB ._. Both_DT lines_NNS were_VBD grown_VBN in_IN a_DT humidified_JJ
          37_CD °_NN C_NNP CO_NNP 
          2_CD incubator_NN until_IN the_DT monolayers_NNS
          reached_VBN about_IN 90_CD %_NN confluence_NN ._. For_IN treatment_NN with_IN
          steroids_NNS ,_, the_DT cells_NNS were_VBD cultured_JJ in_IN complete_JJ medium_NN ,_, in_IN
          which_WDT the_DT serum_NN was_VBD replaced_VBN by_IN charcoal-stripped_JJ serum_NN
          overnight_JJ ._. Cells_NNP were_VBD treated_VBN with_IN 20_CD nM_NN testosterone_NN for_IN
          6_CD hr_NN ._. The_DT cells_NNS were_VBD harvested_VBN with_IN trypsin_NN /_NN EDTA_NNP
          solution_NN ,_, washed_VBN ,_, and_CC subjected_VBN to_TO further_JJ analyses_NNS ._.
        
        
          Intracellular_NNP flow_NN cytometry_NN for_IN analysis_NN of_IN IL-_NNP 6_CD
          and_CC phospho-_NN STAT_NNP 3_CD
          NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS were_VBD grown_VBN as_IN described_VBN
          above_IN ._. For_IN analysis_NN of_IN IL-_NNP 6_CD production_NN ,_, the_DT cells_NNS were_VBD
          fixed_VBN in_IN Cytofix_NNP (_( Pharmingen_NNP )_) for_IN 30_CD min_NN on_IN ice_NN ,_, then_RB
          washed_VBN and_CC permeabilized_JJ with_IN Cytoperm_NNP (_( Pharmingen_NNP )_) for_IN
          15_CD min_NN on_IN ice_NN ._. After_IN washing_VBG with_IN Perm_NNP /_NN Wash_NNP buffer_NN
          (_( Pharmingen_NNP )_) ,_, cells_NNS were_VBD incubated_JJ in_IN 5_CD -_: 10_CD mg_NN /_NN ml_NN goat_NN Ig_NNP
          for_IN 1_CD hr_NN on_IN ice_NN ._. Cells_NNP were_VBD washed_VBN three_CD times_NNS in_IN
          Perm_NNP /_NN Wash_NNP buffer_NN ,_, then_RB incubated_JJ with_IN 1_CD μg_NN biotinylated_JJ
          anti-rat_JJ IL-_NNP 6_CD (_( Pharmingen_NNP )_) /_NN 10_CD 6_CD cells_NNS in_IN 100_CD l_NN Perm_NNP /_NN Wash_NNP
          buffer_NN for_IN 1_CD hr_NN on_IN ice_NN ._. After_IN washing_VBG with_IN Perm_NNP /_NN Wash_NNP
          buffer_NN three_CD times_NNS (_( first_JJ wash_NN being_VBG a_DT 1_CD hr_NN period_NN in_IN
          which_WDT the_DT cells_NNS remain_VBP in_IN Perm_NNP /_NN Wash_NNP buffer_NN for_IN 1_CD hr_NN on_IN
          ice_NN )_) ,_, cells_NNS were_VBD incubated_JJ with_IN phycoerythrin-labeled_JJ
          streptavidin_NN (_( Pharmingen_NNP )_) for_IN 1_CD hr_NN on_IN ice_NN ,_, and_CC washed_VBD
          three_CD times_NNS as_IN described_VBN for_IN the_DT Ab_NNP incubation_NN step_NN ,_, then_RB
          brought_VBN to_TO 1_CD ml_NN with_IN PBS_NNP [_NN 28_CD ]_NN ._.
          For_IN analysis_NN of_IN phospho-_NN STAT_NNP 3_CD ,_, a_DT different_JJ method_NN was_VBD
          used_VBN to_TO visualize_VB the_DT phosphorylated_JJ protein_NN species_NNS ._.
          NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS were_VBD grown_VBN in_IN the_DT presence_NN or_CC
          absence_NN of_IN testosterone_NN ,_, as_IN described_VBN above_IN ._. Cells_NNP were_VBD
          fixed_VBN in_IN Fix_NNP &_CC Perm_NNP Medium_NNP A_DT (_( Caltag_NNP )_) for_IN 10_CD min_NN at_IN
          room_NN temperature_NN ._. After_IN washing_VBG twice_RB in_IN PBS_NNP ,_, cells_NNS were_VBD
          resuspended_JJ in_IN ice-cold_JJ methanol_NN with_IN vortexing_VBG ,_, then_RB
          allow_VB to_TO sit_VB for_IN 15_CD min_NN on_IN ice_NN ._. After_IN washing_VBG twice_RB in_IN
          PBS_NNP ,_, cells_NNS were_VBD resuspended_JJ in_IN Fix_NNP &_CC Perm_NNP Medium_NNP B_NNP
          (_( Caltag_NNP )_) and_CC allowed_VBN to_TO remain_VB at_IN room_NN temperature_NN for_IN 30_CD
          min_NN ._. Medium_NNP B_NNP contained_VBD 2_CD mg_NN /_NN ml_NN goat_NN Ig_NNP for_IN blocking_VBG
          non-specific_JJ binding_JJ ._. After_IN washing_VBG three_CD times_NNS
          (_( including_VBG a_DT 30_CD min_NN time_NN in_IN cold_JJ PBS_NNP for_IN the_DT first_JJ wash_NN )_) ,_,
          the_DT cells_NNS were_VBD incubated_JJ with_IN rabbit_NN anti-phospho-_JJ STAT_NNP 3_CD
          (_( Biosource_NNP )_) ,_, 1_CD μg_NN Ab_NNP /_NN 10_CD 6_CD cells_NNS in_IN 100_CD μl_NN buffer_NN ._. The_DT Ab_NNP
          is_VBZ specific_JJ for_IN the_DT phosphorylated_JJ form_NN of_IN STAT_NNP 3_CD ;_: it_PRP does_VBZ
          not_RB bind_NN to_TO unphosphorylated_JJ STAT_NNP 3_CD or_CC to_TO other_JJ
          phosphorylated_JJ signaling_VBG intermediates_NNS ._. After_IN incubating_VBG
          for_IN 1_CD hr_NN on_IN ice_NN ,_, the_DT cells_NNS were_VBD washed_VBN ,_, with_IN a_DT long_JJ
          period_NN in_IN PBS_NNP for_IN the_DT first_JJ wash_NN as_IN described_VBN above_IN ._. Next_JJ
          cells_NNS were_VBD incubated_JJ with_IN phycoerythrin-labeled_JJ goat_NN
          anti-rabbit_JJ F_NN (_( ab_NN 
          2_LS )_) '_POS (_( Caltag_NNP )_) for_IN 1_CD hr_NN on_IN ice_NN ,_, and_CC
          washed_VBD as_IN described_VBN ._. For_IN analysis_NN ,_, cells_NNS were_VBD brought_VBN to_TO
          1_CD ml_NN in_IN PBS_NNP ._. All_DT flow_NN cytometric_JJ analyses_NNS were_VBD performed_VBN
          on_IN a_DT Becton-_NNP Dickinson_NNP FACScan_NNP ,_, using_VBG CellQuest_NNP software_NN
          for_IN acquisition_NN and_CC analysis_NN ._.
        
        
          Treatment_NNP of_IN NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS with_IN
          dexamethasone_NN
          NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS or_CC clones_NNS (_( see_VB below_IN )_) were_VBD
          seeded_VBN at_IN 10_CD 5_CD cells_NNS /_NN well_RB in_IN microtiter_NN plates_NNS in_IN the_DT
          presence_NN or_CC absence_NN of_IN dexamethasone_NN (_( Sigma_NNP )_) at_IN 0_CD ._. 1_CD and_CC 1_CD
          μM_NN ._. After_IN 48_CD hr_NN ,_, NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS replicate_VB
          wells_NNS of_IN cells_NNS were_VBD harvested_VBN with_IN either_DT trypsin_NN /_NN EDTA_NNP
          (_( GIBCO_NNP )_) or_CC 0_CD ._. 15_CD M_NNP NaCl_NNP /_NN 0_CD ._. 01_CD M_NNP Na_NNP citrate_NN buffer_NN
          (_( citrate-saline_JJ buffer_NN )_) ,_, and_CC the_DT cells_NNS were_VBD processed_VBN for_IN
          intracellular_NN flow_NN cytometry_NN to_TO analyze_VB IL-_NNP 6_CD production_NN ,_,
          as_IN described_VBN above_IN ._.
        
        
          Cloning_NNP NRP-_NNP 154_CD cells_NNS by_IN limit-dilution_JJ
          Washed_NNP NRP-_NNP 154_CD cells_NNS were_VBD diluted_VBN to_TO 10_CD cells_NNS /_NN ml_NN in_IN
          complete_JJ medium_NN ,_, and_CC 100_CD l_NN /_NN well_RB of_IN diluted_VBN cells_NNS were_VBD
          placed_VBN in_IN wells_NNS of_IN a_DT microtiter_NN plate_NN ._. An_DT additional_JJ 100_CD
          μl_NN /_NN well_RB complete_JJ medium_NN were_VBD added_VBN ,_, and_CC the_DT cells_NNS were_VBD
          incubated_JJ until_IN growth_NN was_VBD noted_VBN ,_, 10_CD days_NNS later_RB ._. At_IN that_DT
          time_NN ,_, 16_CD /_NN 96_CD wells_NNS had_VBD cells_NNS growing_VBG in_IN them_PRP (_( 16_CD ._. 7_CD %_NN
          cloning_VBG efficiency_NN )_) ,_, while_IN the_DT remaining_VBG wells_NNS did_VBD not_RB ._.
          Medium_NNP was_VBD replaced_VBN ,_, and_CC plate_NN was_VBD incubated_JJ until_IN cells_NNS
          had_VBD grown_VBN enough_RB to_TO be_VB removed_VBN to_TO bigger_JJR wells_NNS ._. Clones_NNP
          were_VBD expanded_VBN ,_, then_RB analyzed_VBD for_IN IL-_NNP 6_CD production_NN ,_, as_IN
          described_VBN above_IN ._.
        
        
          Analysis_NNP of_IN NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS for_IN
          expression_NN of_IN IL-_NNP 6_CD receptor_NN
          Harvested_NNP NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS were_VBD washed_VBN twice_RB
          in_IN cold_JJ FACS_NNP buffer_NN (_( PBS_NNP /_NN 0_CD ._. 1_LS %_NN serum_NN /_NN 0_CD ._. 01_CD %_NN NaN_NNP 
          3_LS )_) ._. Cells_NNP were_VBD blocked_VBN by_IN incubation_NN
          on_IN ice_NN in_IN goat_NN Ig_NNP (_( Sigma_NNP )_) ,_, 2_CD mg_NN /_NN ml_NN ,_, for_IN 45_CD min_NN ._. After_IN
          washing_VBG twice_RB ,_, cells_NNS were_VBD incubated_JJ with_IN 1_CD or_CC 2_CD μg_NN /_NN 10_CD
          6_CD cells_NNS in_IN 100_CD μl_NN biotinylated_JJ goat_NN anti-human_JJ IL-_NNP 6_CD
          receptor_NN (_( ligand-affinity_JJ purified_JJ ;_: R_NN &_CC D_NNP Systems_NNPS )_) on_IN
          ice_NN for_IN 45_CD min_NN ._. After_IN washing_VBG three_CD times_NNS ,_, cells_NNS were_VBD
          incubated_JJ with_IN phycoerythrin-labeled_JJ streptavidin_NN for_IN 45_CD
          min_NN on_IN ice_NN ._. After_IN washing_VBG three_CD times_NNS ,_, cells_NNS were_VBD
          analyzed_VBN on_IN the_DT flow_NN cytometer_NN ._.
        
        
          Treatment_NNP of_IN NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS with_IN
          AG_NNP 490_CD
          The_DT tyrphostin_NN protein_NN kinase_NN inhibitor_NN AG_NNP 490_CD was_VBD
          purchased_VBN from_IN Calbiochem_NNP ._. It_PRP was_VBD dissolved_VBN in_IN DMSO_NNP ,_, and_CC
          stored_VBD at_IN -_: 20_CD °_NN C_NNP in_IN single-use_JJ aliquots_NNS ._. NRP-_NNP 152_CD and_CC
          cloned_VBN NRP-_NNP 154_CD cells_NNS were_VBD placed_VBN in_IN 60_CD mm_NN wells_NNS ,_, and_CC
          treated_VBD with_IN AG_NNP 490_CD for_IN 48_CD hrs_NNS ._. The_DT cells_NNS were_VBD removed_VBN
          with_IN trypsin_NN ,_, and_CC stained_JJ after_IN washing_VBG with_IN FITC-annexin_NNP
          V_NNP (_( 5_CD μl_NN /_NN 10_CD 6_CD cells_NNS ;_: Caltag_NNP )_) for_IN 15_CD min_NN at_IN room_NN
          temperature_NN ._. Apoptotic_NNP cells_NNS (_( cells_NNS staining_VBG with_IN
          FITC-annexin_NNP V_NNP )_) were_VBD quantified_VBN by_IN measuring_VBG green_JJ
          fluorescence_NN in_IN FL_NNP 1_CD on_IN the_DT flow_NN cytometer_NN ._. CellQuest_NNP
          software_NN was_VBD used_VBN to_TO acquire_VB and_CC analyze_VB the_DT data_NNS ._.
          STATView_NNP software_NN was_VBD used_VBN to_TO perform_VB statistical_JJ
          analyses_NNS ._.
        
      
      
        Results_NNS
        
          Determination_NNP of_IN the_DT phosphorylation_NN state_NN of_IN STAT_NNP 3_CD
          in_IN NRP-_NNP 152_CD &_CC NRP-_NNP 154_CD cells_NNS
          We_PRP had_VBD very_RB preliminary_JJ data_NNS ,_, from_IN a_DT microarray_NN
          experiment_NN comparing_VBG the_DT RNA_NNP of_IN NRP-_NNP 152_CD to_TO NRP-_NNP 154_CD cells_NNS ,_,
          which_WDT indicated_VBD that_IN STAT_NNP 3_CD might_MD be_VB over-expressed_JJ on_IN
          NRP-_NNP 154_CD cells_NNS relative_JJ to_TO NRP-_NNP 152_CD cells_NNS (_( data_NNS not_RB shown_VBN )_) ._.
          Since_IN STAT_NNP 3_CD is_VBZ active_JJ only_RB when_WRB phosphorylated_JJ ,_, we_PRP
          decided_VBD to_TO confirm_VB these_DT preliminary_JJ results_NNS by_IN looking_VBG
          for_IN phospho-_NN STAT_NNP 3_CD in_IN both_DT cell_NN lines_NNS by_IN intracellular_NN
          flow_NN cytometry_NN ._. We_PRP observed_VBD that_IN STAT_NNP 3_CD was_VBD constitutively_RB
          phosphorylated_JJ in_IN NRP-_NNP 154_CD ,_, but_CC not_RB NRP-_NNP 152_CD cells_NNS ._. Even_RB
          when_WRB treated_VBN with_IN testosterone_NN as_IN described_VBN in_IN Materials_NNPS
          and_CC Methods_NNP ,_, NRP-_NNP 152_CD cells_NNS did_VBD not_RB exhibit_VB phosphorylated_JJ
          STAT_NNP 3_CD (_( Figure_NN 1_LS )_) ._. These_DT data_NNS indicate_VBP that_IN the_DT
          over-expressed_JJ STAT_NNP 3_CD observed_VBD in_IN NRP-_NNP 154_CD cells_NNS in_IN the_DT
          gene_NN microarray_NN was_VBD putatively_RB active_JJ as_IN a_DT transcription_NN
          factor_NN ,_, since_IN the_DT amount_NN of_IN phospho-_NN STAT_NNP 3_CD in_IN NRP-_NNP 154_CD
          cells_NNS was_VBD increased_VBN relative_JJ to_TO NRP-_NNP 152_CD cells_NNS ._.
        
        
          IL-_NNP 6_CD is_VBZ produced_VBN constitutively_RB by_IN NRP-_NNP 152_CD and_CC
          NRP-_NNP 154_CD cells_NNS
          In_IN order_NN to_TO determine_VB if_IN IL-_NNP 6_CD was_VBD the_DT activating_VBG
          ligand_NN for_IN phosphorylation_NN of_IN STAT_NNP 3_CD ,_, we_PRP examined_VBD IL-_NNP 6_CD
          expression_NN in_IN untreated_JJ NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS by_IN
          intracellular_NN flow_NN cytometry_NN ._. While_IN both_DT cell_NN lines_NNS made_VBD
          IL-_NNP 6_CD ,_, NRP-_NNP 154_CD cells_NNS displayed_VBD a_DT different_JJ pattern_NN ,_, in_IN
          that_DT there_EX was_VBD a_DT peak_NN of_IN cells_NNS negative_JJ for_IN IL-_NNP 6_CD (_( Figure_NN
          2_LS )_) ._. This_DT may_MD have_VB been_VBN due_JJ to_TO heterogeneity_NN of_IN the_DT
          NRP-_NNP 154_CD cells_NNS ,_, since_IN the_DT parental_JJ lines_NNS had_VBD not_RB been_VBN
          subcloned_JJ by_IN us_PRP ._. Therefore_RB ,_, we_PRP derived_VBD 16_CD clones_NNS of_IN
          NRP-_NNP 154_CD cells_NNS by_IN limit-dilution_JJ cloning_VBG ,_, and_CC examined_VBD
          these_DT for_IN level_NN of_IN IL-_NNP 6_CD expression_NN ._. We_PRP observed_VBD that_IN 9_CD
          clones_NNS were_VBD highly-positive_JJ for_IN IL-_NNP 6_CD ,_, while_IN the_DT rest_NN
          expressed_VBD little_JJ IL-_NNP 6_CD ,_, thereby_RB accounting_NN for_IN the_DT 2_CD peaks_NNS
          we_PRP observed_VBD in_IN the_DT parental_JJ NRP-_NNP 154_CD line_NN (_( Figure_NN 3_LS )_) ._.
        
        
          IL-_NNP 6_CD receptor_NN was_VBD expressed_VBN on_IN the_DT surfaces_VBZ of_IN
          NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS
          When_WRB we_PRP examined_VBD NRP-_NNP 152_CD and_CC uncloned_JJ NRP-_NNP 154_CD cells_NNS
          for_IN expression_NN of_IN the_DT IL-_NNP 6_CD receptor_NN ,_, we_PRP observed_VBD that_IN all_DT
          NRP-_NNP 152_CD cells_NNS expressed_VBD the_DT IL-_NNP 6_CD receptor_NN ,_, while_IN the_DT
          uncloned_JJ NRP-_NNP 154_CD cells_NNS had_VBD a_DT population_NN that_IN apparently_RB
          did_VBD not_RB express_VB the_DT receptor_NN (_( Figure_NN 4_LS )_) ._. In_IN studies_NNS
          currently_RB underway_NN ,_, we_PRP are_VBP analyzing_VBG the_DT 16_CD NRP-_NNP 154_CD
          clones_NNS we_PRP derived_VBD for_IN differences_NNS in_IN IL-_NNP 6_CD receptor_NN
          expression_NN ,_, and_CC to_TO see_VB if_IN there_EX is_VBZ any_DT correlation_NN with_IN
          levels_NNS of_IN IL-_NNP 6_CD expression_NN ._.
        
        
          Effect_NN of_IN dexamethasone_NN treatment_NN on_IN NRP-_NNP 152_CD and_CC
          NRP-_NNP 154_CD cells_NNS
          To_TO examine_VB the_DT role_NN of_IN autocrine_NN IL-_NNP 6_CD on_IN NRP-_NNP 152_CD and_CC
          NRP-_NNP 154_CD cells_NNS ,_, we_PRP looked_VBD at_IN the_DT effect_NN of_IN dexamethasone_NN
          treatment_NN on_IN IL-_NNP 6_CD expression_NN on_IN both_DT cell_NN lines_NNS ,_, and_CC on_IN
          high_JJ and_CC low_JJ IL-_NNP 6_CD -_: expressing_VBG clones_NNS of_IN NRP-_NNP 154_CD cells_NNS ._.
          Dexamethasone_NNP is_VBZ known_VBN to_TO inhibit_VB IL-_NNP 6_CD synthesis_NN by_IN
          acting_VBG at_IN the_DT steroid-response_JJ elements_NNS of_IN the_DT IL-_NNP 6_CD
          promoter_NN ._. NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS were_VBD routinely_RB grown_VBN
          in_IN the_DT presence_NN of_IN dexamethasone_NN ,_, so_IN the_DT effect_NN on_IN
          proliferation_NN was_VBD not_RB quantified_VBN ._. In_IN the_DT following_VBG
          experiments_NNS ,_, we_PRP used_VBD dexamethasone-free_JJ medium_NN ,_, and_CC also_RB
          treated_VBD the_DT serum_NN twice_RB with_IN activated_VBN charcoal_NN ,_, to_TO
          remove_VB endogenous_JJ steroids_NNS (_( stripped_VBN serum_NN )_) ,_, then_RB added_VBD
          defined_VBN amounts_NNS of_IN dexamethasone_NN for_IN carying_VBG out_RP the_DT
          experiments_NNS ._. We_PRP observed_VBD that_DT dexamethasone_NN treatment_NN of_IN
          NRP-_NNP 152_CD cells_NNS inhibited_VBD IL-_NNP 6_CD synthesis_NN without_IN affecting_VBG
          NRP-_NNP 152_CD growth_NN ,_, as_IN expected_VBN ._. In_IN contrast_NN ,_, dexamethasone_NN
          treatment_NN of_IN NRP-_NNP 154_CD cells_NNS did_VBD not_RB inhibit_VB IL-_NNP 6_CD
          synthesis_NN ;_: instead_RB dexamethasone_NN treatment_NN apparently_RB
          enhanced_VBD IL-_NNP 6_CD production_NN (_( panel_NN B_NNP )_) ._. This_DT effect_NN was_VBD
          observed_VBN for_IN high_JJ and_CC low_JJ IL-_NNP 6_CD -_: expressing_VBG clones_NNS of_IN
          NRP-_NNP 154_CD (_( Figure_NN 5_CD ,_, panels_NNS C_NNP and_CC D_NNP )_) ,_, and_CC therefore_RB was_VBD
          independent_JJ of_IN IL-_NNP 6_CD production_NN by_IN the_DT cells_NNS ._. However_RB ,_,
          clones_NNS expressing_VBG low_JJ amounts_NNS of_IN IL-_NNP 6_CD expressed_VBD less_JJR
          enhancement_NN of_IN IL-_NNP 6_CD production_NN that_IN clones_NNS expressing_VBG
          high_JJ amounts_NNS of_IN IL-_NNP 6_CD (_( Figure_NN 5_CD ,_, panels_NNS C_NNP and_CC D_NNP )_) ._.
        
        
          Inhibition_NNP of_IN JAK_NNP 2_CD induced_VBN apoptosis_NNS in_IN NRP-_NNP 152_CD but_CC
          not_RB NRP-_NNP 154_CD clones_NNS
          In_IN continuing_VBG our_PRP$ studies_NNS on_IN the_DT role_NN of_IN IL-_NNP 6_CD in_IN STAT_NNP 3_CD
          phosphorylation_NN ,_, we_PRP used_VBD the_DT JAK_NNP 2_CD phosphorylation_NN
          inhibitor_NN AG_NNP 490_CD ,_, to_TO see_VB if_IN inhibiting_VBG JAK_NNP 2_CD
          phosphorylation_NN would_MD inhibit_VB survival_NN of_IN NRP-_NNP 152_CD or_CC
          NRP-_NNP 154_CD cells_NNS ,_, as_IN had_VBD been_VBN described_VBN for_IN LNCaP_NNP cells_NNS
          previously_RB [_NN 29_CD ]_NN ._. We_PRP examined_VBD clones_NNS of_IN NRP-_NNP 154_CD ,_,
          selected_VBN by_IN amount_NN of_IN IL-_NNP 6_CD expression_NN each_DT had_VBD :_: 2_CD high_JJ
          IL-_NNP 6_CD -_: expressing_VBG clones_NNS and_CC 2_CD low-_JJ IL-_NNP 6_CD -_: expressing_VBG clones_NNS
          were_VBD used_VBN for_IN these_DT experiments_NNS ._. Treatment_NNP with_IN the_DT JAK_NNP 2_CD
          inhibitor_NN for_IN 48_CD hrs_NNS induced_VBD apoptosis_NNS ,_, measured_VBN by_IN
          cellular_JJ binding_JJ of_IN FITC-annexin_NNP V_NNP ,_, in_IN NRP-_NNP 152_CD but_CC not_RB
          NRP-_NNP 154_CD clones_NNS (_( Table_NNP 1_LS )_) ._. We_PRP detected_VBD no_DT effect_NN of_IN the_DT
          vehicle_NN (_( DMSO_NNP )_) at_IN the_DT highest_JJS concentration_NN used_VBN ._. Our_PRP$
          data_NNS imply_VBP that_IN JAK_NNP 2_CD -_: mediated_JJ phosphorylation_NN of_IN STAT_NNP 3_CD
          was_VBD essential_JJ for_IN the_DT survival_NN of_IN NRP-_NNP 152_CD cells_NNS ,_, but_CC that_IN
          NRP-_NNP 154_CD cells_NNS did_VBD not_RB require_VB activated_VBN JAK_NNP 2_CD for_IN
          survival_NN ,_, regardless_RB of_IN amount_NN of_IN IL-_NNP 6_CD produced_VBN by_IN the_DT
          cell_NN ._. Further_RB experiments_NNS are_VBP underway_NN to_TO determine_VB if_IN
          STAT_NNP 3_CD requires_VBZ phosphorylation_NN by_IN a_DT different_JJ kinase_NN ,_,
          such_JJ as_IN JAK_NNP 1_CD ,_, in_IN NRP-_NNP 154_CD cells_NNS ._.
        
      
      
        Discussion_NNP
        We_PRP observed_VBD that_IN STAT_NNP 3_CD was_VBD constitutively_RB phosphorylated_JJ
        in_IN NRP-_NNP 154_CD ,_, but_CC not_RB NRP-_NNP 152_CD cells_NNS (_( Figure_NN 1_LS )_) ._. Treatment_NNP of_IN
        NRP-_NNP 154_CD cells_NNS with_IN testosterone_NN did_VBD not_RB increase_VB the_DT level_NN
        of_IN phosphorylation_NN in_IN NRP-_NNP 154_CD cells_NNS (_( data_NNS not_RB shown_VBN )_) ._. Even_RB
        after_IN testosterone_NN treatment_NN ,_, STAT_NNP 3_CD was_VBD not_RB phosphorylated_JJ
        in_IN NRP-_NNP 152_CD cells_NNS (_( data_NNS not_RB shown_VBN )_) ._. There_EX is_VBZ evidence_NN that_DT
        androgen_NN treatment_NN may_MD increase_VB the_DT survival_NN of_IN PCA_NNP cells_NNS
        through_IN activation_NN of_IN STAT_NNP 3_CD [_NN 29_CD ]_NN ._. Further_RB experiments_NNS
        are_VBP underway_NN to_TO test_VB this_DT possibility_NN ._. STAT_NNP 1_CD ,_, another_DT
        signaling_VBG intermediate_JJ in_IN the_DT IL-_NNP 6_CD pathway_NN ,_, has_VBZ been_VBN
        observed_VBN to_TO be_VB activated_VBN in_IN non-tumorigenic_JJ cells_NNS ,_, and_CC may_MD
        function_VB as_RB a_DT "_'' check_NN "_'' for_IN STAT_NNP 3_CD phosphorylation_NN ,_, a_DT possible_JJ
        oncogenic_JJ event_NN [_NN 30_CD 31_CD ]_NN ._. We_PRP are_VBP investigating_VBG whether_IN or_CC
        not_RB STAT_NNP 1_CD is_VBZ phosphorylated_JJ by_IN JAK_NNP 2_CD in_IN NRP-_NNP 152_CD cells_NNS ,_, and_CC
        whether_IN STAT_NNP 1_CD phosphorylation_NN is_VBZ required_VBN for_IN the_DT survival_NN
        of_IN NRP-_NNP 152_CD cells_NNS ._. These_DT results_NNS would_MD explain_VB why_WRB we_PRP saw_VBD an_DT
        effect_NN of_IN AG_NNP 490_CD on_IN NRP-_NNP 152_CD cells_NNS ,_, in_IN the_DT absence_NN of_IN
        phospho-_NN STAT_NNP 3_CD in_IN these_DT cells_NNS (_( Table_NNP 1_LS )_) ._.
        We_PRP looked_VBD at_IN the_DT effect_NN of_IN anti-rat_JJ IL-_NNP 6_CD Ab_NNP on_IN both_DT
        NRP-_NNP 152_CD or_CC NRP-_NNP 154_CD cell_NN growth_NN rate_NN ,_, but_CC were_VBD unable_JJ to_TO
        detect_VB an_DT effect_NN ,_, using_VBG 3_CD H-_NNP thymidine_NN incorporation_NN to_TO
        measure_VB proliferation_NN (_( data_NNS not_RB shown_VBN )_) ._. We_PRP think_VBP this_DT is_VBZ
        due_JJ to_TO failure_NN to_TO reach_VB high_JJ enough_RB Ab_NNP
        (_( commercially-available_JJ anti-rat_JJ IL-_NNP 6_CD )_) concentrations_NNS
        necessary_JJ to_TO neutralize_NN the_DT IL-_NNP 6_CD produced_VBN by_IN the_DT NRP-_NNP 154_CD
        cells_NNS (_( highest_JJS concentration_NN achieved_VBN was_VBD only_RB 20_CD μg_NN /_NN ml_NN )_) ._.
        We_PRP are_VBP limited_JJ in_IN performing_VBG Ab_NNP studies_NNS by_IN the_DT lack_NN of_IN
        commercially-available_JJ rat-specific_JJ reagents_NNS ._. However_RB ,_, we_PRP
        are_VBP using_VBG alternative_JJ strategies_NNS in_IN more_JJR experiments_NNS
        currently_RB underway_NN to_TO determine_VB the_DT role_NN of_IN IL-_NNP 6_CD in_IN STAT_NNP 3_CD
        activation_NN to_TO answer_VB this_DT important_JJ question_NN in_IN NRP-_NNP 154_CD
        cells_NNS ._.
        We_PRP found_VBD that_DT dexamethasone_NN treatment_NN of_IN NRP-_NNP 152_CD cells_NNS
        inhibited_VBD IL-_NNP 6_CD synthesis_NN without_IN affecting_VBG cell_NN growth_NN ._. In_IN
        contrast_NN ,_, dexamethasone_NN treatment_NN of_IN NRP-_NNP 154_CD cells_NNS did_VBD not_RB
        inhibit_VB IL-_NNP 6_CD synthesis_NN ;_: instead_RB dexamethasone_NN treatment_NN
        eliminated_VBD the_DT IL-_NNP 6_CD negative_JJ peak_NN and_CC enhanced_VBN IL-_NNP 6_CD
        production_NN albeit_IN to_TO a_DT smaller_JJR extent_NN in_IN low_JJ
        IL-_NNP 6_CD -_: expressing_VBG clones_NNS (_( Figure_NN 5_CD ,_, panel_NN D_NNP )_) ._. Enhancement_NNP of_IN
        IL-_NNP 6_CD production_NN by_IN dexamethasone_NN treatment_NN has_VBZ been_VBN
        previously_RB observed_VBN in_IN Kaposi_NNP 's_POS sarcoma_NN cells_NNS [_NN 32_CD ]_NN ._. In_IN
        the_DT case_NN of_IN NRP-_NNP 154_CD cells_NNS ,_, the_DT steroid-responsive_JJ element_NN
        for_IN dexamethasone_NN on_IN the_DT IL-_NNP 6_CD promoter_NN may_MD have_VB been_VBN
        mutated_VBN to_TO a_DT form_NN that_WDT does_VBZ not_RB bind_NN steroid_NN receptors_NNS ._.
        Mutations_NNP in_IN the_DT IL-_NNP 6_CD promoter_NN region_NN may_MD play_VB a_DT role_NN in_IN
        the_DT tumorigenic_JJ effects_NNS of_IN constitutive_JJ IL-_NNP 6_CD expression_NN in_IN
        prostatic_JJ carcinoma_NN cells_NNS [_NN 33_CD ]_NN ._. Such_JJ polymorphisms_NNS have_VBP
        been_VBN described_VBN for_IN the_DT IL-_NNP 6_CD receptor_NN in_IN Kaposi_NNP 's_POS sarcoma_NN ,_,
        and_CC are_VBP believed_VBN to_TO play_VB a_DT role_NN in_IN IL-_NNP 6_CD -_: mediated_JJ
        progression_NN of_IN this_DT type_NN of_IN cancer_NN [_NN 32_CD ]_NN ._.
        We_PRP observed_VBD that_DT inhibition_NN of_IN STAT_NNP 3_CD activation_NN by_IN
        treatment_NN with_IN AG_NNP 490_CD ,_, which_WDT inhibits_NNS JAK_NNP 2_CD activation_NN ,_,
        resulted_VBD in_IN apoptosis_NNS of_IN NRP-_NNP 152_CD but_CC not_RB NRP-_NNP 154_CD cells_NNS
        (_( Table_NNP 1_LS )_) ._. A_DT possible_JJ explanation_NN of_IN the_DT data_NNS would_MD be_VB the_DT
        use_NN of_IN JAK_NNP 1_CD for_IN phosphorylation_NN of_IN STAT_NNP 3_CD in_IN NRP-_NNP 154_CD cells_NNS ,_,
        which_WDT would_MD not_RB be_VB inhibited_VBD by_IN AG_NNP 490_CD ._. IL-_NNP 6_CD receptor_NN
        binding_JJ activates_NNS JAK_NNP 1_CD as_RB well_RB as_IN JAK_NNP 2_CD ,_, which_WDT in_IN turn_NN
        phosphorylates_NNS STAT_NNP 3_CD [_NN 14_CD ]_NN ._. This_DT in_IN fact_NN has_VBZ been_VBN shown_VBN
        to_TO be_VB the_DT case_NN for_IN v-src-transformed_JJ fibroblasts_NNS [_NN 34_CD ]_NN ._.
        Another_DT hypothesis_NNS is_VBZ that_IN STAT_NNP 3_CD activation_NN in_IN NRP-_NNP 154_CD
        cells_NNS is_VBZ not_RB dependent_JJ upon_IN a_DT signaling_VBG cascade_NN ,_, but_CC is_VBZ
        constitutive_JJ ,_, possibly_RB due_JJ to_TO a_DT mutation_NN not_RB unlike_IN that_DT
        contained_VBD within_IN the_DT cSTAT_NN 3_CD plasmid_NN generated_VBN by_IN Bromberg_NNP ,_,
        et_CC al_NN ._. [_NN 35_CD ]_NN ._. We_PRP are_VBP investigating_VBG in_IN detail_NN the_DT
        signaling_VBG pathway_NN in_IN NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS to_TO answer_VB
        these_DT important_JJ questions_NNS ._.
        The_DT importance_NN of_IN STAT_NNP 3_CD activation_NN via_IN IL-_NNP 6_CD in_IN prostatic_JJ
        cancer_NN development_NN has_VBZ been_VBN suggested_VBN by_IN previous_JJ
        investigators_NNS ._. For_IN example_NN ,_, IL-_NNP 6_CD acting_VBG via_IN its_PRP$ receptor_NN
        has_VBZ been_VBN shown_VBN to_TO activate_VBP STAT_NNP 3_CD in_IN LNCaP_NNP cells_NNS ._. IL-_NNP 6_CD given_VBN
        exogenously_RB ,_, since_IN LNCaP_NNP cells_NNS do_VBP not_RB produce_VB IL-_NNP 6_CD ,_,
        resulted_VBD in_IN increased_VBN growth_NN of_IN the_DT cells_NNS concomitant_NN with_IN
        activation_NN of_IN STAT_NNP 3_CD [_NN 36_CD ]_NN ._. LNCaP_NNP cells_NNS transfected_JJ with_IN a_DT
        plasmid_NN conferring_VBG constitutive_JJ IL-_NNP 6_CD expression_NN
        demonstrated_VBN increased_VBN growth_NN ,_, relative_JJ to_TO untransfected_JJ or_CC
        sham-transfected_JJ cells_NNS [_NN 36_CD ]_NN ._. However_RB ,_, other_JJ
        investigators_NNS have_VBP observed_VBN that_IN IL-_NNP 6_CD treatment_NN of_IN LNCaP_NNP
        cells_NNS reulted_JJ in_IN terminal_NN differentiation_NN and_CC inhibition_NN of_IN
        growth_NN ,_, associated_VBN with_IN STAT_NNP 3_CD activation_NN [_NN 17_CD 37_CD 38_CD ]_NN ._. The_DT
        molecular_JJ basis_NN for_IN the_DT apparent_JJ contradiction_NN is_VBZ unknown_JJ
        at_IN this_DT time_NN ._. Continued_VBN use_NN of_IN the_DT NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cell_NN
        lines_NNS in_IN parallel_JJ experiments_NNS should_MD be_VB useful_JJ in_IN
        elucidating_VBG the_DT discrepancies_NNS among_IN various_JJ
        laboratories_NNS ._.
        It_PRP is_VBZ possible_JJ that_IN exogenous_JJ or_CC autocrine_NN IL-_NNP 6_CD is_VBZ not_RB
        required_VBN for_IN constitutive_JJ STAT_NNP 3_CD activation_NN in_IN NRP-_NNP 154_CD
        cells_NNS ._. For_IN example_NN ,_, viral_JJ IL-_NNP 6_CD might_MD be_VB incorporated_VBN into_IN
        the_DT genomes_NNS of_IN prostatic_JJ carcinomas_NNS ,_, as_IN has_VBZ been_VBN described_VBN
        for_IN Kaposi_NNP sarcoma_NN [_NN 5_CD 32_CD 33_CD 39_CD 40_CD 41_CD ]_NN ._. The_DT route_NN of_IN
        introduction_NN of_IN the_DT viral_JJ IL-_NNP 6_CD is_VBZ believed_VBN to_TO be_VB through_IN
        previous_JJ herpesvirus_JJ infection_NN [_NN 39_CD 41_CD ]_NN ._. Another_DT
        possibility_NN is_VBZ that_IN the_DT insertion_NN of_IN the_DT oncogene_NN BRCA_NNP 1_CD
        results_NNS in_IN the_DT constitutive_JJ activation_NN of_IN STAT_NNP 3_CD in_IN NRP-_NNP 154_CD
        cells_NNS ,_, as_IN has_VBZ been_VBN described_VBN in_IN Du-_NNP 145_CD prostate_NN cancer_NN
        cells_NNS [_NN 42_CD ]_NN ._. Du-_NNP 145_CD cells_NNS do_VBP not_RB make_VB IL-_NNP 6_CD ;_: nor_CC are_VBP they_PRP
        dependent_JJ upon_IN it_PRP for_IN continued_VBN proliferation_NN in_IN vitro_NN ._.
        However_RB ,_, they_PRP were_VBD dependent_JJ upon_IN STAT_NNP 3_CD activation_NN for_IN
        survival_NN ,_, as_IN demonstrated_VBN by_IN experiments_NNS in_IN which_WDT
        anti-sense_JJ oligomucleotides_NNS for_IN STAT_NNP 3_CD were_VBD incoporated_JJ by_IN
        Du-_NNP 145_CD cells_NNS [_NN 42_CD ]_NN ._. We_PRP are_VBP currently_RB performing_VBG similar_JJ
        experiments_NNS to_TO determine_VB if_IN IL-_NNP 6_CD is_VBZ a_DT necessary_JJ ligand_NN for_IN
        the_DT activation_NN and_CC survival_NN of_IN NRP-_NNP 154_CD cells_NNS ._.
        In_IN summary_NN ,_, we_PRP have_VBP demonstrated_VBN that_IN a_DT major_JJ difference_NN
        between_IN NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS is_VBZ that_IN NRP-_NNP 154_CD cells_NNS
        over-express_JJ the_DT gene_NN for_IN STAT_NNP 3_CD ,_, relative_JJ to_TO NRP-_NNP 152_CD cells_NNS ,_,
        and_CC untreated_JJ NRP-_NNP 154_CD cells_NNS ._. Furthermore_RB ,_, NRP-_NNP 154_CD cells_NNS
        express_VBP constitutively-activated_JJ STAT_NNP 3_CD ,_, while_IN NRP-_NNP 152_CD cells_NNS
        do_VBP not_RB ._. Moreover_RB ,_, we_PRP found_VBD that_IN while_IN both_DT cell_NN lines_NNS
        synthesized_JJ IL-_NNP 6_CD constitutively_RB ,_, only_RB the_DT IL-_NNP 6_CD production_NN
        of_IN NRP-_NNP 152_CD cells_NNS was_VBD inhibited_VBD by_IN dexamethasone_NN treatment_NN
        (_( Figure_NN 5_LS )_) ._. Finally_RB ,_, we_PRP demonstrated_VBD that_IN while_IN both_DT cell_NN
        lines_NNS expressed_VBD the_DT IL-_NNP 6_CD receptor_NN on_IN their_PRP$ surfaces_VBZ ,_, the_DT
        patterns_NNS were_VBD different_JJ ._. NRP-_NNP 154_CD cells_NNS had_VBD a_DT subpopulation_NN
        of_IN cells_NNS which_WDT did_VBD not_RB stain_VB with_IN anti-_NN IL-_NNP 6_CD receptor_NN Ab_NNP ,_,
        while_IN all_PDT the_DT NRP-_NNP 152_CD cells_NNS stained_JJ with_IN Ab_NNP to_TO the_DT IL-_NNP 6_CD
        receptor_NN ._. Although_IN the_DT results_NNS presented_VBN above_IN give_VB us_PRP more_JJR
        insight_NN into_IN the_DT role_NN of_IN IL-_NNP 6_CD in_IN PCA_NNP ,_, they_PRP do_VBP not_RB tell_VB us_PRP
        if_IN constitutive_JJ STAT_NNP 3_CD activation_NN is_VBZ a_DT determining_VBG factor_NN in_IN
        the_DT change_NN to_TO prostate_NN neoplasia_NN ,_, or_CC if_IN anti-apoptotic_JJ
        factors_NNS induced_VBN by_IN STAT_NNP 3_CD play_VB a_DT role_NN in_IN prostatic_JJ
        neoplasia_NN ._.
      
      
        Conclusions_NNP
        We_PRP have_VBP shown_VBN that_IN NRP-_NNP 152_CD and_CC NRP-_NNP 154_CD cells_NNS exhibit_NN
        fundamental_JJ differences_NNS in_IN the_DT regulation_NN of_IN IL-_NNP 6_CD
        production_NN by_IN dexamethasone_NN ,_, and_CC in_IN the_DT requirement_NN for_IN
        JAK_NNP 2_CD -_: mediated_JJ events_NNS for_IN survival_NN ._. The_DT tumorigenic_JJ line_NN
        NRP-_NNP 154_CD expressed_VBD phospho-_NN STAT_NNP 3_CD under_IN normal_JJ growth_NN
        condition_NN ,_, while_IN the_DT non-tumorigenic_JJ line_NN did_VBD not_RB ._. These_DT
        data_NNS indicate_VBP a_DT very_RB important_JJ role_NN for_IN STAT_NNP 3_CD in_IN conferring_VBG
        the_DT neoplastic_JJ state_NN on_IN prostatic_JJ epithelial_NN cells_NNS ,_, and_CC
        point_NN out_RP the_DT future_JJ direction_NN of_IN our_PRP$ laboratory_NN 's_POS
        investigations_NNS ._.
      
      
        List_NN of_IN abbreviations_NNS
        PCA_NNP prostate_NN cancer_NN
        DMEM_NNP Dulbecco_NNP 's_POS modification_NN of_IN Eagle_NNP 's_POS medium_NN
        GAPDH_NNP glyceraldehyde_NN phosphate_NN dehydrogenase_NN
        IMDM_NNP Iscove_NNP 's_POS modification_NN of_IN Dulbecco_NNP 's_POS medium_NN
        PBS_NNP phosphate-buffered_JJ saline_NN FITC_NNP fluorescein_NN
        isothiocyanate_NN
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
